Genentech's Hemlibra: Clinical Outcome Assessment Data Only Partially Swayed US FDA
Executive Summary
Hemophilia A drug's labeling reflects data on physical function improvement because FDA deemed that portion of the Haem-A-QoL instrument fit for purpose, while other questions were viewed as insensitive to change or irrelevant. Review documents suggest agency was unimpressed with results from a health status instrument frequently used in economic analyses.
You may also be interested in...
US FDA’s Streamlined Drug Approval Packages Shine Less Light On Sponsor Interactions
CDER is no longer proactively posting mid- and late-cycle meeting minutes and certain correspondence with sponsors for new drug and biologic approvals; drugs center says it is focused on ensuring the most scientifically meaningful information is prioritized and posted in a timely manner, but some observers say the change raises transparency concerns.
US FDA’s Streamlined Drug Approval Packages Shine Less Light On Sponsor Interactions
CDER is no longer proactively posting mid- and late-cycle meeting minutes and certain correspondence with sponsors for new drug and biologic approvals; drugs center says it is focused on ensuring the most scientifically meaningful information is prioritized and posted in a timely manner, but some observers say the change raises transparency concerns.
Keeping Track: A Fresh Wave Of Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.